Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | CCR8 | P51685 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15398809 | 0.75 | CYP19A1 (0.32) | KDM4ENPC1RAB9AMAPTATM | |
| SCHEMBL1424929 | 0.73 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTATM | |
| SCHEMBL745547 | 0.71 | KDM4E (0.53) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL5922 | 0.68 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL29351528 | 0.68 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL29907716 | 0.68 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL3711450 | 0.68 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL16026844 | 0.66 | KDM4E (0.93) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL8655605 | 0.66 | KDM4E (0.93) | KDM4ENPC1RAB9AMAPTATM | |
| Dipyridyl SCHEMBL15136892 | 0.66 | KDM4E (0.93) | KDM4ENPC1RAB9AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | claimed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | claimed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | claimed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | claimed |
| EP-3216798-A2 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2017-09-13 | — | — | EP | disclosed |
| EP-2673285-B1 | KETOLIDE COMPOUNDS | WOCKHARDT LTD (IN) | 2017-07-19 | — | — | EP | disclosed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-01-02 | — | — | US | disclosed |
| EP-2673285-A1 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2013-12-18 | — | — | EP | disclosed |
| US-5089490-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | disclosed |
| US-4758556-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0127847-A1 | 7-Oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene derivatives | HOECHST UK LIMITED (GB) | 1984-12-12 | — | — | EP | disclosed |
| US-4399131-A | Cephem derivatives | HOECHST AG (DE) | 1983-08-16 | — | — | US | disclosed |
| US-4278793-A | ANTIBIOTICS, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4201779-A | 7[(2-Amino-thiazol-4-yl)glyoxylamido]-cephem derivatives and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-06 | — | — | US | disclosed |
| US-4016159-A | BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083412-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | KDM4E 313/4885NPC1 452/4885RAB9A 891/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | KDM4E 3077/4885NPC1 50/4885RAB9A 377/4885 |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | KDM4E 298/4885NPC1 458/4885RAB9A 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.